Urologic DiseasesNCT04763837
Migration of Intraureteral Stents Compared to Conventional Double-J Stents.
A study testing Intraureteral stent and Conventional Double-J stent in people with Urologic Diseases and Urological System Complication of Procedure, run by University of Louisville.
Trial summary
The purpose of this study is to determine if stents placed with only one loop in the kidney move more than stents placed with a loop in both the kidney and a bladder. Participants in this study will undergo placement of a stent into the ureter that drains urine from the kidney into the bladder. Read more about this study
- Who is it for?
- Ages 1 year to 100 yearsHealthy volunteers can take part
- Conditions the study is for
- Urologic Diseases, Urological System Complication of Procedure
- What is being tested?
- Intraureteral stent and Conventional Double-J stent
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- No sites listed yet
- Study dates
- Feb 2027to Apr 2028
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 year to 100 years
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- Those undergoing ureteral stent placement for nephrolithiasis, hydronephrosis, and urological cancer.
Who cannot join
- none
About this study
The purpose of this study is to determine if stents placed with only one loop in the kidney move more than stents placed with a loop in both the kidney and a bladder. Participants in this study will undergo placement of a stent into the ureter that drains urine from the kidney into the bladder. The stent will be placed in 1 of 2 ways: either with only a loop of the stent is left in the kidney or in the regular manner where a loop of the stent is left in both the kidney and in the bladder. The position of the stent will be measured at the time of placement. When the stent is removed, the position of the stent will be measured prior to pulling the stent.
Read the detailed description
The ureteral stent is one of the most extensively used tools in the field of urology. They are used for aiding post-operative healing of the ureter, visualizing the ureteral during procedures, and alleviating ureteral obstruction (eg. nephrolithiasis). Double-J stents, which are secured by loops in both the renal pelvis and the bladder, have become most urologists' go-to choice for ureteral stents since they were introduced in the 1970s. Unfortunately, it has been shown that 80-90% of patients with ureteral stents have urinary complaints following stent placement.
Interestingly, a recent study suggested utility of intraureteral stents. These stents have one loop in the renal pelvis while their distal end is positioned proximal to the ureteral orifice. The above-mentioned study showed that patients with intraureteral stents had less discomfort as opposed to the those that had double-J stents.
Due to the immense number of patients that require ureteral stent placement, this improvement in comfort is very promising for the urological field. However, no one has studied if stents placed intraureterally migrate from the time they are placed to the time they are removed. If stents migrate proximally toward the renal pelvis, it is possible that retrieval could be more difficult, and the ureteral patency established by the stent could be compromised.
The objective of this study is to determine if intraureterally placed stents migrate as compared to ureteral stents placed via the conventional method.
This study will be a prospective, randomized controlled, single-blinded trial. The subjects will include up to 140 patients (about 70 subjects per group) from ages 1-100 years old that are to undergo stent placement for nephrolithiasis, hydronephrosis, and urological cancer.
Prior to the procedure, each patient that has agreed to participate in this study will be randomly assigned to receive a stent placed intraureterally or a stent placed in the conventional manner. After each intraureteral stent is placed via cystoscopy, the distance of the distal end of the stent to the ureteral orifice will be measured via fluoroscopy that was calibrated prior to the procedure. After each double-J stent is placed via cystoscopy, the length of stent that is present in the bladder will also be measured using calibrated fluoroscopy . Subjects will not be informed of which group they are assigned to. When the patients return for stent removal, the previously mentioned distances will be measured again prior to pulling the stent. They will also be asked to complete the ureteral stent symptom questionnaire (USSQ) to assess stent-associated discomfort. The primary endpoint of the study would be stent migration distance (mm). Secondary endpoints would include patient comfort level.
All medical records will be accessed on secure devices and networks. All subjects will be assigned a subject number upon enrolled in the study. When a researcher needs to record data from a patient's medical records, they will record this information with the patient's corresponding subject number. Only the researchers involved in this study will have access to the document that includes patient identifiers and their subject number. At the conclusion of this study, the document with patient identifiers and subject numbers will be destroyed.
Data will be collected from electronic medical records of patients from ULP (University of Louisville Physicians) Urology.
- Being tested
- Intraureteral stent, Conventional Double-J stent
- Keywords
- urology, ureteral stent
- Medical subject headings
- Urologic Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Intraureteral stentDevice
Also called Polaris™ Loop Ureteral Stent - Boston Scientific
This intervention involves the placement of an intraureteral stent, a tube that drains urine from the kidney to the bladder and has a loop of tube only in the kidney and NOT in the bladder. The distal end of the tube will stay in the ureter just proximal to the opening to the bladder.
Conventional Double-J stentDevice
This intervention involves the placement of a conventional double-J stent, a tube that drains urine from the kidney to the bladder and has a loop of tube in both the kidney and in the bladder.
| Study group | Role | What they receive |
|---|---|---|
| Intraureteral stent group | Experimental | Patients assigned to this group will undergo placement of an intraureteral stent, a tube that drains urine from the kidney to the bladder and has a loop of tube in only in the kidney and NOT in the bladder. This group will be the experimental group. Receives: Device: Intraureteral stent |
| Conventional Double-J stent | Active comparator | Patients assigned to this group will undergo placement of a double-J ureteral stent, a tube that drains urine from the kidney to the bladder and has a loop of tube in both the kidney and the bladder. This group will serve as the control. Receives: Device: Conventional Double-J stent |
What is being measured
The primary outcome is the main question the study is designed to answer.
Stent migration
The distance that the stent migrates into the bladder or into the kidney.
Measured: 12 months
Secondary outcomes (1)
Patient comfort level
Patient comfort level, as assessed via the Ureteral stent symptom questionnaire (USSQ).
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Feb 2021
- Study startFeb 2027 (estimated)
- Primary completionApr 2028 (estimated)
- Study completionApr 2028 (estimated)
Why it stopped: unable to continue
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Urologic DiseasesStudies of the same condition, open and under way.
- More trials run by University of LouisvilleThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This study will be a prospective, randomized controlled, single-blinded trial. The subjects will include up to 140 patients (about 70 subjects per group) from ages 1-100 years old that are to undergo stent placement for nephrolithiasis, hydronephrosis, and urological cancer. They will be randomized to one of two groups: intraureteral stent or conventional double-J stent. Upon removal of the stent, migration distance will be measured via fluoroscopy using a calibrated x-ray system.
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Louisville
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Kellen Choi, University of Louisville
- Investigators
- Kellen B Choi, DO, FACOS, Principal investigator, Associate Professor, University of Louisville Department of Urology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04763837
- Sponsor's protocol ID
- 20.0563
- Status last verified
- Apr 2022
- First submitted
- 28 Jan 2021
- Last updated
- 29 Apr 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Publications
Finney RP. Experience with new double J ureteral catheter stent. 1978. J Urol. 2002 Feb;167(2 Pt 2):1135-8; discussion 1139. doi: 10.1016/s0022-5347(02)80361-5. No abstract available.
PubMed 11905888Joshi HB, Okeke A, Newns N, Keeley FX Jr, Timoney AG. Characterization of urinary symptoms in patients with ureteral stents. Urology. 2002 Apr;59(4):511-6. doi: 10.1016/s0090-4295(01)01644-2.
PubMed 11927301Pollard SG, Macfarlane R. Symptoms arising from Double-J ureteral stents. J Urol. 1988 Jan;139(1):37-8. doi: 10.1016/s0022-5347(17)42282-8.
PubMed 2961892Yoshida T, Inoue T, Taguchi M, Matsuzaki T, Murota T, Kinoshita H, Matsuda T. Efficacy and Safety of Complete Intraureteral Stent Placement versus Conventional Stent Placement in Relieving Ureteral Stent Related Symptoms: A Randomized, Prospective, Single Blind, Multicenter Clinical Trial. J Urol. 2019 Jul;202(1):164-170. doi: 10.1097/JU.0000000000000196. Epub 2019 Jun 7.
PubMed 30829132Joshi HB, Newns N, Stainthorpe A, MacDonagh RP, Keeley FX Jr, Timoney AG. Ureteral stent symptom questionnaire: development and validation of a multidimensional quality of life measure. J Urol. 2003 Mar;169(3):1060-4. doi: 10.1097/01.ju.0000049198.53424.1d.
PubMed 12576846
Study at a glance
From the registry record, last updated by the sponsor on 29 Apr 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Migration of Intraureteral Stents Compared to Conventional Double-J Stents.
- ClinicalTrials.gov ID
- NCT04763837
- Acronym / sponsor ID
- 20.0563
- Keywords
- urology, ureteral stent
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: unable to continue
- Enrolment
- 0 participants (actual)
- Lead sponsor
- University of LouisvilleUniversity, hospital or other
- Study start
- Feb 2027 (estimated)
- Primary completion
- Apr 2028 (estimated)
- Study completion
- Apr 2028 (estimated)
- First posted
- 21 Feb 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine if stents placed with only one loop in the kidney move more than stents placed with a loop in both the kidney and a bladder. Participants in this study will undergo placement of a stent into the ureter that drains urine from the kidney into the bladder. The stent will be placed in 1 of 2 ways: either with only a loop of the stent is left in the kidney or in the regular manner where a loop of the stent is left in both the kidney and in the bladder. The position of the stent will be measured at the time of placement. When the stent is removed, the position of the stent will be measured prior to pulling the stent.
Detailed description
The ureteral stent is one of the most extensively used tools in the field of urology. They are used for aiding post-operative healing of the ureter, visualizing the ureteral during procedures, and alleviating ureteral obstruction (eg. nephrolithiasis). Double-J stents, which are secured by loops in both the renal pelvis and the bladder, have become most urologists' go-to choice for ureteral stents since they were introduced in the 1970s. Unfortunately, it has been shown that 80-90% of patients with ureteral stents have urinary complaints following stent placement.
Interestingly, a recent study suggested utility of intraureteral stents. These stents have one loop in the renal pelvis while their distal end is positioned proximal to the ureteral orifice. The above-mentioned study showed that patients with intraureteral stents had less discomfort as opposed to the those that had double-J stents.
Due to the immense number of patients that require ureteral stent placement, this improvement in comfort is very promising for the urological field. However, no one has studied if stents placed intraureterally migrate from the time they are placed to the time they are removed. If stents migrate proximally toward the renal pelvis, it is possible that retrieval could be more difficult, and the ureteral patency established by the stent could be compromised.
The objective of this study is to determine if intraureterally placed stents migrate as compared to ureteral stents placed via the conventional method.
This study will be a prospective, randomized controlled, single-blinded trial. The subjects will include up to 140 patients (about 70 subjects per group) from ages 1-100 years old that are to undergo stent placement for nephrolithiasis, hydronephrosis, and urological cancer.
Prior to the procedure, each patient that has agreed to participate in this study will be randomly assigned to receive a stent placed intraureterally or a stent placed in the conventional manner. After each intraureteral stent is placed via cystoscopy, the distance of the distal end of the stent to the ureteral orifice will be measured via fluoroscopy that was calibrated prior to the procedure. After each double-J stent is placed via cystoscopy, the length of stent that is present in the bladder will also be measured using calibrated fluoroscopy . Subjects will not be informed of which group they are assigned to. When the patients return for stent removal, the previously mentioned distances will be measured again prior to pulling the stent. They will also be asked to complete the ureteral stent symptom questionnaire (USSQ) to assess stent-associated discomfort. The primary endpoint of the study would be stent migration distance (mm). Secondary endpoints would include patient comfort level.
All medical records will be accessed on secure devices and networks. All subjects will be assigned a subject number upon enrolled in the study. When a researcher needs to record data from a patient's medical records, they will record this information with the patient's corresponding subject number. Only the researchers involved in this study will have access to the document that includes patient identifiers and their subject number. At the conclusion of this study, the document with patient identifiers and subject numbers will be destroyed.
Data will be collected from electronic medical records of patients from ULP (University of Louisville Physicians) Urology.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
- Model description
- This study will be a prospective, randomized controlled, single-blinded trial. The subjects will include up to 140 patients (about 70 subjects per group) from ages 1-100 years old that are to undergo stent placement for nephrolithiasis, hydronephrosis, and urological cancer. They will be randomized to one of two groups: intraureteral stent or conventional double-J stent. Upon removal of the stent, migration distance will be measured via fluoroscopy using a calibrated x-ray system.
| Arm | Type | Receives |
|---|---|---|
| Intraureteral stent group | Experimental | Device: Intraureteral stentPatients assigned to this group will undergo placement of an intraureteral stent, a tube that drains urine from the kidney to the bladder and has a loop of tube in only in the kidney and NOT in the bladder. This group will be the experimental group. |
| Conventional Double-J stent | Active comparator | Device: Conventional Double-J stentPatients assigned to this group will undergo placement of a double-J ureteral stent, a tube that drains urine from the kidney to the bladder and has a loop of tube in both the kidney and the bladder. This group will serve as the control. |
Who may qualify
- Ages
- 1 year to 100 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- Those undergoing ureteral stent placement for nephrolithiasis, hydronephrosis, and urological cancer.
Key exclusion criteria (1 listed)
- none
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Intraureteral stentAlso: Polaris™ Loop Ureteral Stent - Boston ScientificThis intervention involves the placement of an intraureteral stent, a tube that drains urine from the kidney to the bladder and has a loop of tube only in the kidney and NOT in the bladder. The distal end of the tube will stay in the ureter just proximal to the opening to the bladder. | Device | Intraureteral stent group |
| Conventional Double-J stentThis intervention involves the placement of a conventional double-J stent, a tube that drains urine from the kidney to the bladder and has a loop of tube in both the kidney and in the bladder. | Device | Conventional Double-J stent |
Primary outcome
Stent migration
Time frame: 12 months
The distance that the stent migrates into the bladder or into the kidney.
1 secondary outcome
Patient comfort level
Time frame: 12 months
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Apr 2022.
- Background: PubMed 11905888Finney RP. Experience with new double J ureteral catheter stent. 1978. J Urol. 2002 Feb;167(2 Pt 2):1135-8; discussion 1139. doi: 10.1016/s0022-5347(02)80361-5. No abstract available.
- Background: PubMed 11927301Joshi HB, Okeke A, Newns N, Keeley FX Jr, Timoney AG. Characterization of urinary symptoms in patients with ureteral stents. Urology. 2002 Apr;59(4):511-6. doi: 10.1016/s0090-4295(01)01644-2.
- Background: PubMed 2961892Pollard SG, Macfarlane R. Symptoms arising from Double-J ureteral stents. J Urol. 1988 Jan;139(1):37-8. doi: 10.1016/s0022-5347(17)42282-8.
- Background: PubMed 30829132Yoshida T, Inoue T, Taguchi M, Matsuzaki T, Murota T, Kinoshita H, Matsuda T. Efficacy and Safety of Complete Intraureteral Stent Placement versus Conventional Stent Placement in Relieving Ureteral Stent Related Symptoms: A Randomized, Prospective, Single Blind, Multicenter Clinical Trial. J Urol. 2019 Jul;202(1):164-170. doi: 10.1097/JU.0000000000000196. Epub 2019 Jun 7.
- Background: PubMed 12576846Joshi HB, Newns N, Stainthorpe A, MacDonagh RP, Keeley FX Jr, Timoney AG. Ureteral stent symptom questionnaire: development and validation of a multidimensional quality of life measure. J Urol. 2003 Mar;169(3):1060-4. doi: 10.1097/01.ju.0000049198.53424.1d.
Related trials for Urologic Diseases
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
Population Pharmacokinetics of Temocillin in Acute Enterobacterial Pyelonephritis in Children
Pyelonephritis
Active, not recruitingPhase 3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Carcinoma, Renal Cell
Recruiting
Safety and Performance of UCon Patch Electrode
Urinary Incontinence, Urinary Incontinence, Urge
Active, not recruitingPhase 2
Safety and Efficacy of Empagliflozin in Hemodialysis
End Stage Renal Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kellen B Choi, DO, FACOS principal investigator
Associate Professor, University of Louisville Department of Urology
Questions about this trial
What is this clinical trial studying?
A study testing Intraureteral stent and Conventional Double-J stent in people with Urologic Diseases and Urological System Complication of Procedure, run by University of Louisville.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 29 Apr 2022. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Stent migration (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04763837, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Apr 2022.